Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
3.
Medicine (Baltimore) ; 98(48): e17948, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31770202

RESUMEN

BACKGROUND: Laser systems are a common treatment choice for onychomycosis. They exert their effects on inhibiting the growth of the fungus by selective photothermolysis but efficacy is dependent on the specific type of apparatus used. To systematically review the available published literature on the curative effects and safety of laser treatment for onychomycosis. METHODS: Databases including PubMed, web of science, China National Knowledge Internet (CNKI), WanFang Database and VIP were searched systematically to identify relevant articles published up to July 2018. Potentially relevant articles were sourced, assessed against eligibility criteria by 2 researchers independently and data were extracted from included studies. A meta-analysis was performed using R software. RESULTS: Thirty-five articles involving 1723 patients and 4278 infected nails were included. Meta-analysis of data extracted from these studies revealed that: the overall mycological cure rate was 63.0% (95%CI 0.53-0.73); the mycological cure rate associated with the 1064-nm Nd: YAG laser was 63.0% (95%CI 0.51-0.74); and that of CO2 lasers was 74.0% (95%CI 0.37-0.98). The published data indicate that laser treatment is relatively safe, but can cause tolerable pain and occasionally lead to bleeding after treatment. CONCLUSION: Laser treatment of onychomycosis is effective and safe. The cumulative cure rate of laser treatment was significantly higher for CO2 lasers than other types of laser. Laser practitioners should be made aware of potential adverse effects such as pain and bleeding.


Asunto(s)
Láseres de Gas/uso terapéutico , Láseres de Estado Sólido/uso terapéutico , Terapia por Luz de Baja Intensidad/métodos , Onicomicosis/radioterapia , Humanos , Uñas/efectos de la radiación , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
4.
Exp Dermatol ; 28(11): 1227-1236, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31386778

RESUMEN

BACKGROUND: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) is a well-known treatment for non-hypertrophic actinic keratoses and superficial basal-cell carcinomas. OBJECTIVES: In this study, we first revealed that ALA-PDT treatment effectively ameliorated the psoriasis-like lesion in imiquimod (IMQ)-induced mouse model and further explored the potential molecular mechanism and related signalling pathways during the treatment. Besides, we also confirmed a significant alleviation of ALA-PDT therapy on IFN-γ-induced over-proliferation of keratinocytes. METHODS: H&E staining was conducted to reveal the histological changes of mice in different groups. The different expression levels of RNA were illustrated by using QRT-PCR. Western blot was performed to confirm the various expression levels of protein in mice. In vitro, cell proliferation and cell cycle were evaluated by cell counting kit-8 and flow cytometry assay, respectively. RESULTS: The result showed that ALA-PDT's anti-proliferation effect and regulation on Socs1/3, JAK1/2 and K17 in IFN-γ-induced keratinocytes were largely weakened by NAC, indicating that ALA-PDT attenuated the proliferation of IFN-γ-induced keratinocytes by enhancing ROS level. CONCLUSIONS: These results demonstrated that ALA-PDT largely activated the productivity of Socs1/3 in a ROS-dependent manner. Socs1/3 is a potential blocker in JAK signalling pathway and inhibits the proliferation and keratinization of keratinocytes in psoriasis.


Asunto(s)
Ácido Aminolevulínico/farmacología , Quinasas Janus/metabolismo , Fotoquimioterapia , Fármacos Fotosensibilizantes/farmacología , Psoriasis/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Femenino , Imiquimod , Interferón gamma , Queratinocitos/efectos de los fármacos , Ratones Endogámicos BALB C , Psoriasis/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Transducción de Señal/efectos de los fármacos , Proteínas Supresoras de la Señalización de Citocinas/metabolismo
5.
Chin Med Sci J ; 32(2): 100-6, 2017 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-28693690

RESUMEN

Objective We investigated the efficacy and safety of 1064 nm Nd: YAG laser, intense pulsed light (IPL), and lauromacrogol injection in the treatment of hemangioma, in order to evaluate the value of color Doppler ultrasound guidance in choosing the optimal treatment modality. Methods Infantile patients who were clinical diagnosed as hemangiomas were randomly divided into group A, who had color Doppler ultrasound examinations before the treatment, and group B who had the treatment without ultrasound evaluation. Patients in the group A were assigned into subgroups according to the depth of lesion by sonography: group A-1 for those who had a lesion depth <1.2 mm, and took intense pulsed light therapy; group A-2 for those who had a lesion depth ≥1.2mm and < 3 mm, and took long pulse 1064 nm Nd:YAG laser therapy; group A-3 for those who had a lesion depth ≥3mm and <5 mm, and were treated by IPL combined with long pulse 1064 nm Nd:YAG laser treatment; Group A-4 for those who had a lesion depth ≥5 mm, and took lauromacrogol injection therapy. Patients in the group B took long pulse 1064 nm Nd:YAG laser treatment without preoperative ultrasound evaluation. The efficacy and adverse reactions of the treatments between the groups were evaluated and compared statistically.Results Totally 113 patients with 128 skin lesions were enrolled in this study, 85 in the group A (mean age 6.8±7.9 months) and 28 in the group B (mean age 6.9±9.9 months). The mean depth of hemangioma was 3.3±1.1 mm in the group A, ranging from 0.5-7.8 mm, with 0.8±0.4 mm, 2.2±0.4 mm, 4.2±0.6 mm and 6.2±0.7 mm in group A1, A2, A3 and A4, respectively. The cure rates and effective rates in the group A were significantly higher than those in the group B (cure rates: 64.5% vs 56.3%, U=3.378, P=0.045; effective rates: 89.5% vs 78.1%, U=4.163, P=0.041). The adverse effect rates of the group A (vesicle 20.0%, pigmentation 46.9%, scarring 17.7%) were lower than those of the group B (vesicle 21.9%, pigmentation 60.4%, scarring 25.0%). Incidences of pigmentation and scarring were statistically significantly different (U=3.884, P=0.034, and U=4.016, P=0.032 respectively) between the two groups.Conclusion With the guidance of color Doppler ultrasound, the efficacy and safety of long pulse 1064 nmNd:YAG laser, intense pulsed light, and lauromacrogol injection in the treatment of infantile hemangioma have better outcomes compared to laser treatment alone without preoperative ultrasound examination.


Asunto(s)
Hemangioma/diagnóstico por imagen , Ultrasonografía Doppler en Color/métodos , Femenino , Hemangioma/patología , Hemangioma/terapia , Humanos , Lactante , Masculino
6.
J Cosmet Laser Ther ; 19(6): 353-359, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28557542

RESUMEN

BACKGROUND: Although systemic and topical antifungal agents are widely used to treat onychomycosis, oral medications can cause adverse effects and the efficacy of topical agents is not satisfying. Currently, laser treatment has been studied for its efficacy in the treatment of onychomycosis. Our study was aimed to evaluate the efficacy of fractional carbon dioxide (CO2) laser treatment combined with terbinafine cream for 6 months in the treatment of onychomycosis and to analyze the influencing factors. METHODS: A total of 30 participants (124 nails) with clinical and mycological diagnosis of onychomycosis received fractional CO2 laser treatment at 2-week interval combined with terbinafine cream once daily for 6 months. The clinical efficacy rate (CER) was assessed from the percentage of fully normal-appearing nails or nails with ≤5% abnormal appearance, and the mycological clearance rate (MCR) was assessed from the percentage of nails with negative fungal microscopy. RESULTS: The CER was evaluated at 3 time points: at the end of treatment (58.9%), at 1 month after the last treatment (63.5%), and at 3 months after the last treatment (68.5%). The MCRs at 1 month and 3 months after the last treatment were 77.4 and 74.2%, respectively. The evaluation of influencing factors showed significantly higher CER (p < 0.05) in nails of participants with age <50 years, distal lateral subungual onychomycosis (DLSO), superficial white onychomycosis (SWO), nail thickness <2 mm, affected first-to-fourth finger/toenails, Trichophyton rubrum, and Trichophyton mentagrophytes. All participants experienced tolerable mild burning sensation during laser treatment, but there were no other adverse reactions reported. CONCLUSIONS: Fractional CO2 laser treatment combined with terbinafine cream for 6 months was an effective and safe method for the treatment of onychomycosis. There were 5 factors that positively influenced the treatment outcome: age, clinical type of onychomycosis, nail thickness, involved nail, and species of fungus.


Asunto(s)
Antifúngicos/uso terapéutico , Láseres de Gas/uso terapéutico , Terapia por Luz de Baja Intensidad/métodos , Naftalenos/uso terapéutico , Onicomicosis/terapia , Adolescente , Adulto , Anciano , Antifúngicos/administración & dosificación , Niño , Terapia Combinada , Femenino , Humanos , Láseres de Gas/efectos adversos , Terapia por Luz de Baja Intensidad/efectos adversos , Masculino , Persona de Mediana Edad , Naftalenos/administración & dosificación , Onicomicosis/tratamiento farmacológico , Onicomicosis/radioterapia , Satisfacción del Paciente , Terbinafina , Adulto Joven
7.
Dermatol Online J ; 22(2)2016 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-27267185

RESUMEN

Photodermatoses are a group of skin conditions associated with an abnormal reaction to ultraviolet (UV) radiation. There are several of the photosensitive rashes which mainly affect the UV exposed areas of the skin. It can be classified into four groups: immunology mediated photodermatoses, chemical and drug induced photosensitivity, photoaggravated dermatoses, and genetic disorders. A systematic approach including history, physical examination, phototesting, photopatch testing, and laboratory tests are important in diagnosis of a photodermatosis patient. In order to optimally treat a disease of photodermatoses, we need to consider which treatment offers the most appropriate result in each disease, such as sunscreens, systemic medication, topical medication, phototherapy, and others. For all groups of photodermatoses, photoprotection is one of the essential parts of management. Photoprotection, which includes sunscreening and wearing photoprotective clothing, a wide brimmed hat, and sunglasses, is important. There are also promising emerging photoprotective agents.


Asunto(s)
Terapia PUVA , Trastornos por Fotosensibilidad/tratamiento farmacológico , Protectores Solares/uso terapéutico , Antimaláricos/uso terapéutico , Antioxidantes/uso terapéutico , Inhibidores de la Calcineurina/uso terapéutico , Glucocorticoides/uso terapéutico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Inmunosupresores/uso terapéutico , Ácido Micofenólico/uso terapéutico , Trastornos por Fotosensibilidad/clasificación , Trastornos por Fotosensibilidad/etiología , Talidomida/uso terapéutico , beta Caroteno/uso terapéutico
8.
Biomed Res Int ; 2016: 3853754, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26998485

RESUMEN

OBJECTIVE: We evaluated synergistic efficacy and safety of combined topical application of Botulinum Toxin Type A (BTX-A) with fractional CO2 laser for facial rejuvenation. METHODS: Twenty female subjects were included for this split-face comparative study. One side of each subject's cheek was treated with fractional CO2 plus saline solution, and the other side was treated with fractional CO2 laser plus topical application of BTX-A. Patients received one session of treatment and evaluations were done at baseline, one, four, and twelve weeks after treatment. The outcome assessments included subjective satisfaction scale; blinded clinical assessment; and the biophysical parameters of roughness, elasticity, skin hydration, transepidermal water loss (TEWL), and the erythema and melanin index. RESULTS: BTX-A combined with fractional CO2 laser sides showed higher physician's global assessment score, subject satisfaction score, roughness, skin hydration, and skin elasticity compared to that of fractional CO2 plus saline solution side at 12 weeks after treatment. TEWL and erythema and melanin index showed no significant differences between two sides at baseline, one, four, and twelve weeks after treatment. CONCLUSION: Topical application of BTX-A could enhance the rejuvenation effect of fractional CO2 laser.


Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Técnicas Cosméticas , Cara , Terapia por Luz de Baja Intensidad/métodos , Piel/metabolismo , Administración Tópica , Adulto , Elasticidad/efectos de los fármacos , Eritema/etiología , Eritema/metabolismo , Femenino , Humanos , Melaninas/metabolismo , Persona de Mediana Edad , Proyectos Piloto , Pérdida Insensible de Agua/efectos de los fármacos
9.
Arch Dermatol Res ; 304(3): 223-8, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22350182

RESUMEN

This study was aimed to investigate the protective effects of ginsenoside Rg1 on 8-methoxypsoralen(8-MOP)/Ultraviolet A (UVA)-induced premature senescence in human fibroblasts, and the underlying mechanism. We established a stress-induced premature senescence model by 8-MOP/UVA irradiation. The aging condition was determined by histochemical staining of senescence-associated ß-galactosidase (SA-ß-gal). Relative telomere length was calculated by the ratio of the amount of telomere DNA versus single copy DNA by real-time polymerase chain reaction, and protein levels of p-P53, p21(WAF-1) and p16(INK-4a) were estimated by Western blotting. Compared with the 8-MOP/UVA treatment group, we found that the irradiated fibroblasts pretreated with ginsenoside Rg1 demonstrated a decrease in the expression of SA-ß-gal, a downregulation in the level of senescence-associated proteins, and a deceleration in telomere shortening. Taken together, these results suggest that ginsenoside Rg1 significantly antagonizes premature senescence induced by 8-MOP/UVA in fibroblasts.


Asunto(s)
Envejecimiento Prematuro/tratamiento farmacológico , Senescencia Celular/efectos de los fármacos , Citoprotección , Fibroblastos/efectos de los fármacos , Ginsenósidos/farmacología , Terapia PUVA/efectos adversos , Telómero/efectos de los fármacos , Línea Celular , Humanos , Acortamiento del Telómero/efectos de los fármacos , beta-Galactosidasa/análisis
10.
Arch Dermatol Res ; 300(6): 331-4, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18401588

RESUMEN

Exposure to ultraviolet B (UVB) irradiation is a major risk factor for the development of skin cancer. Therefore, it is important to identify agents that can offer protection against UVB-caused DNA damage. Photocarcinogenesis is caused largely by mutations at the sites of incorrectly repaired DNA photoproducts, of which the most common are the cyclobutane pyrimidine dimers (CPDs). In this study, a DNA damage model of UVB irradiation-induced fibroblasts was established. The immunocytochemical staining, immuno dot blotting and Western blotting were employed in the study. We demonstrated that pre-treatment of fibroblasts with Baicalin dose-dependently reduced the amount of UVB-generated CPDs. Compared with UVB irradiated cells, UVB-induced p53 accumulation was less pronounced in Baicalin-treated cells. Taken together, these results suggest that Baicalin prevent CPDs formation induced by UVB. Baicalin is therefore a promising protective substance against UVB radiation.


Asunto(s)
Daño del ADN/efectos de la radiación , Fibroblastos/efectos de la radiación , Flavonoides/farmacología , Dímeros de Pirimidina/efectos de la radiación , Células Cultivadas , Preescolar , Daño del ADN/efectos de los fármacos , Daño del ADN/genética , Relación Dosis-Respuesta a Droga , Medicamentos Herbarios Chinos/farmacología , Exposición a Riesgos Ambientales/efectos adversos , Fibroblastos/química , Fibroblastos/metabolismo , Humanos , Lactante , Recién Nacido , Masculino , Dímeros de Pirimidina/química , Dímeros de Pirimidina/genética , Proteína p53 Supresora de Tumor/antagonistas & inhibidores , Proteína p53 Supresora de Tumor/genética , Rayos Ultravioleta/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA